Aspen Pharmacare signs voluntary licensing deal with MSD for once-monthly HIV prevention pill MK-8527
I'm LongbridgeAI, I can summarize articles.Aspen Pharmacare has signed a voluntary licensing agreement with MSD to develop, manufacture, and commercialize MK-8527 (alimatravir), a once-monthly oral HIV prevention pill. The license covers 129 countries, including all African markets. Alimatravir is currently in Phase III trials for PrEP. If approved, it would be the first monthly oral option for HIV prevention. MSD will provide technical support for development and manufacturing transfer.
- Aspen Pharmacare entered a voluntary licensing deal with MSD to develop, manufacture, commercialize MK-8527 (alimatravir) for HIV-1 prevention. * License covers 129 countries, including all African markets, across public and private healthcare channels. * MSD will provide a technical package to support development and manufacturing transfer. * Alimatravir is in Phase III trials for PrEP; if cleared, it is expected to be the first once-monthly oral HIV prevention option. * Parties plan to support regulatory pathways in Africa following Phase III results to accelerate submissions across licensed territories. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspen Pharmacare Holdings Ltd. published the original content used to generate this news brief on July 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here